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Abstract Lymphomas originating from the lymphatic sys-
tem comprise about 30 entities classified according to the
World Health Organization (WHO). The histopathological
diagnosis is generally considered difficult and prone to
mistakes. Since non-random chromosomal translocations are
specifically involved in different lymphoma entities, their
detection will be increasingly important. Hence, a split-
signal fluorescence in situ hybridisation (FISH) procedure
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would be helpful in discriminating the most difficult
classifications. The Euro-FISH programme, a concerted
action of nine European laboratories, has validated a robust,
standardised protocol to improve the diagnostic approach on
lymphoma entities. Therefore, 16 fluorescent probes and 10
WHO entities, supplemented with reactive cases, were
selected. The results of the Euro-FISH programme show
that all probes were correctly cytogenetically located, that
the standardised protocol is robust, resulting in reliable
results in approximately 90% of cases, and that the procedure
could be implemented in every laboratory, bringing the
relatively easy interpretation of split-signal probes within the
reach of many pathology laboratories.
Keywords Split-signal FISH . Lymphoma . Validation .
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Introduction
The Euro-FISH project represents a concerted multi-centre
initiative in the field of lymphoma diagnosis. These can-
cers, which originate from the immune system, differ widely
in their clinical behaviour and in terms of the therapy needed.
The diagnosis of lymphomas can be a complex process,
which needs to take into account clinical, morphological,
immunophenotypic and genetic features. Different lympho-
ma types are associated with non-random chromosomal
translocations (Table 1) and the detection of these aberra-
tions is a fundamental step in the identification of the dif-
ferent entities.
For example, Burkitt lymphoma (BL), a highly aggres-
sive lymphoma, is associated with a translocation involving
c-myc gene in more than 90% of cases [1]. In over 95% of
mantle cell lymphomas (MCL), a t(11;14)(q13;q32) is
found involving the cyclin D1 and IGH genes [2]. In
addition, a translocation of the BCL2 gene to the IgH gene
locus resulting in a t(14;18) is a hallmark of follicular
lymphoma [3] and is only seen in 20–30% of the diffuse
large B cell lymphoma (DLBCL) IGH translocations.
Furthermore, in DLBCL, 14% show 3q27 aberrations and
14% display MYC rearrangement (Mitelman Database of
Chromosome Aberrations in Cancer 2006; http://cgap.nci.
nih.gov/Chromosomes/Mitelman).
Moreover, some cytogenetic alterations define clinically
relevant subgroups and are, therefore, crucial for therapy
decisions. For instance, gastric marginal zone lymphomas
(gastric MALT lymphomas) lacking the t(11;18) involving
the MALT1 gene respond to Helicobacter pylori eradication
therapy in contrast to the t(11;18)-positive cases that do not
respond [4].
Based on these and other available data, it is of increasing
importance to know the underlying recurring chromosomal
aberrations. In this way, initial correct patient-tailored
therapy can be given, preventing over- or under-treatment.
At present, these cytogenetic abnormalities are not easily
detected in the routine laboratory. Cytogenetic analysis,
based on banding techniques, will present an overview of
all cytogenetic aberrations. However, lack of success in
culturing tumour cells, low mitotic indices and the lack of
fresh material often complicates the use of this technolo-
gy for routine diagnosis. In a recent review [5], it was
nicely outlined that fluorescence in situ hybridisation
(FISH) has, over the last decade, become a firmly estab-
lished technique.
To detect a translocation in a tumour cell, one can use
probes with different colours on different chromosomes
(usually two) in such a way that, in the case of a trans-
location, a fusion signal occurs (Fig. 1a). This procedure is
feasible in cytospins or preparations of isolated nuclei, but
more difficult in tissue sections where many nuclei are cut
and thus a complete signal is present in a minority of cells,
Table 1 Selection of lymphoma entities and frequently found translocations (as taken from the World Health Organization Classification of
Tumours, Pathology and Genetics, Tumours of Haematopoietic and Lymphoid Tissues by Jaffe [13])
Selected entity Associated translocation Percentage
Diffuse large B cell lymphoma (DLBCL) t(14;18) (IGH; 14q32) (BCL2;18q21) and 3q27 abnormalities (BCL6) 20–30
30
Mantle cell lymphoma (MCL) t(11;14)(q13;q32) (cyclin D1; 11q13) (IGH; 14q32) 70–75
Lymphocytic leukaemia (B-CLL/SLL) t(14;18) (q32;q21) (IGH; 14q32) (BCL2;18q21) 5–10
Follicular lymphoma (FCL) t(14;18) (q32;q21) (IGH; 14q32) (BCL2;18q21) 70–95
Gastric MALT t(11;18)(q21;q22) (MLT; 18q22) 30
Splenic marginal zone lymphoma (MZL) Allelic loss 7q21–32 40
Burkitt lymphoma (BL) t(8;14)(q24;q32) (MYC; 8q24) 100
Lymphoplasmacytic lymphoma (LPL) t(9;14)(p13;q32) (pax5; 9p13) 5
Anaplastic large cell lymphoma (ALCL) t(2;5)(p23;q35) (ALK; 2p23) 70
T lymphoblastic lymphoma (T-LBL) T cell receptor alpha and delta (14q11) (TCRAD) beta 7q35 (TCRB),
gamma 7p14 (TCRG) (T cell receptor loci, approximately 33%) TCL1
30
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making interpretation cumbersome. Split-signal or break-
apart probes use differently coloured probes on both sides
of a known breakpoint region, resulting in a fused signal in
the normal situation, but single colours when a break in the
gene occurs (Fig. 1b). This approach is advantageous in
tissue sections since each single coloured signal indicates a
specific chromosomal break.
The Euro-FISH programme consisted of three stages:
probe validation, protocol development and testing, appli-
cation of the protocol to be used throughout Europe and
was started in order to validate a robust, standardised FISH
protocol using split-signal probes on formalin-fixed, paraffin-
embedded tissue sections. The validity of the diagnostic
approach on selected entities of lymphomas was also
evaluated. This standardised protocol, when implemented,
will be a useful tool in discerning the different types of
lymphoma and available treatment options.
Materials and methods
The Euro-FISH project was organised into three stages:
Stage 0, probe validation on metaphase slides of B
lymphocytes of healthy donors. Stage 1, robustness of the
standardised Euro-FISH protocol. In this stage, the Euro-
FISH protocol was tested in each laboratory on a
laboratory-specific tissue microarray (TMA). Stage 2, the
evaluation of the FISH protocol throughout Europe. The
Euro-FISH protocol was tested on 144 cases, on four
TMAs with all entities and laboratories equally represented.
The evaluation involved testing of 16 FISH probes on 10
different World Health Organization (WHO) lymphoma
entities; diffuse large B cell lymphoma (DLBCL), mantle
cell lymphoma (MCL), lymphocytic leukaemia (B-CLL/
SLL), follicular lymphoma (FCL), gastric marginal zone
lymphoma (gastric MALT), splenic marginal zone lympho-
ma (splenic MZL), African and non-African BL, lympho-
plasmacytic lymphoma (LPL), anaplastic large cell
lymphoma (ALCL), all ALK+ and T lymphoblastic
lymphoma (T-LBL), supplemented with reactive tissues
(spleen, tonsil, lymph node and thymus). All samples were
neutral-buffered, formalin-fixed.
Probes and FISH procedures
Split-signal FISH probes (Table 2), Histology FISH
Accessory Kit (code no. K5599), Cytology FISH Accessory
Kit (code no. K5499), Dako Hybridiser system (code no.
S2451), Whirlpool JT356 or JT359 microwaves and meta-
phase slides of B lymphocytes (DR2524 lot:20050627mem)
of healthy donors were supplied byDako (DakoDenmarkA/S,
Produktionsvej 42, DK-2600 Glostrup, Denmark). All fluo-
rescent microscopes were equipped with microscope-specific
double filters (XF53, Omega Optical, Brattleboro, VT, USA)
suitable for the fluorescein isothiocyanate- and Texas red-
labelled split-signal probes. Paraffin-embedded, neutral-
buffered, formalin-fixed biopsies were used in stages 1
and 2. Probes used during the Euro-FISH procedure with
corresponding cytogenetic position and code numbers are
listed in Table 2. During stages 0, 1 and 2, each laboratory
Fig. 1 Schematic representation of nucleus stained with a fusion
probe (a) and a split-signal probe (b) to detect a chromosomal
translocation in a tumour cell. a Red and green need to co-localise to
detect a known translocation (right-hand side) whereas a split-signal
probe (b) detects a break without the need to know the translocation
partner (right-hand side)
Table 2 Split-signal probes with corresponding cytogenetic locali-
sation and Dako code number
Probe Cytogenetic
position
Code no.
BCL10 1p22 Y5418
IGK 2p11 Y5416
ALK 2p23 Y5417
BCL6 3q27 Y5408
TCRG 7p14 Y5420
TCRB 7q34 Y5421
MYC 8q24 Y5410
PAX5 9p13 Y5413
CCND1 11q13 Y5414
TCRAD 14q11 Y5419
TCL1 14q32 Y5426
IGH 14q32 Y5406
MALT1 18q21 Y5409
BCL2 18q21 Y5407
BCL3 19q13 Y5411
IGL 22q11 Y5412
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tested four probes resulting in laboratory-independent
duplicates. Probes were assigned to the laboratories in
such a way that duplicates were in general not generated
by the same two laboratories (Table 3). Slides were stained
according to the manufacturer’s manual.
Probe validation
Each probe was validated by analysing at least five meta-
phases of B lymphocytes of healthy donors per laboratory.
Metaphase slides were stained and mounted by using the
Cytology FISH Accessory Kit according to the manufac-
turer’s manual. Chromosomes were identified by inverted
4′,6-diamidino-2-phenylindole (DAPI) staining. All probes
were validated in duplicate. Therefore, eight laboratories
each validated four probes.
Case selection
From the archives of each participating laboratory, cases
were selected for the studies. All protocols for obtaining
and studying human tissues and cells were approved by
each institution’s review board for human subject research.
The cases had been diagnosed using classic pathological
criteria based on morphology and immunophenotype and
molecular criteria. No form of translocation detection had
been part of the diagnostic process. A central review was
not performed. Stages 1 and 2 TMAs were prepared with
the 10 above-mentioned WHO lymphoma entities, supple-
mented with reactive cases.
Tissue microarrays
To prepare TMAs, punch needles of 1 mm were used. For
stage 1, laboratories prepared TMAs using tissue blocks
from their own institutes, resulting in a laboratory-specific
TMA. Stage 2 TMAs were made centrally at the Depart-
ment of Pathology, Radboud University Nijmegen Medical
Centre, Nijmegen, The Netherlands, such that every entity
and every institute was equally represented. The position of
the cores taken from the tissues, used to prepare the TMAs,
was based upon hematoxylin and eosin-stained slides.
Stage 1 TMAs were composed of three or four entities,
preferably six cases per entity, per laboratory (see also
Table 3) supplemented with DLBCL (three cases per TMA)
and reactive tissues (three cases per TMA) resulting in 24 to
30 cores per TMA. The four stage 2 TMAs consisted of 36
cores each, in total 144 cases; 12 African BL, 12 non-
African BL, 12 ALCL, 12 B-CLL/SLL, 16 DLBCL, 12
FCL, 12 LPL, 12 gastric MALT, 12 MCL, 12 splenic MZL,
12 T-LBL and eight reactive tissues.
Of both stage 1 and 2 TMAs, 3 μm sections were cut,
put on glass slides, stained and mounted using the
Histology FISH Accessory Kit according to the manufac-
turer’s manual.
During stage 1, laboratories used their own optimal
digestion times. Optionally, a 6-min digestion time (if
different from the laboratories own optimal digestion time)
was used. In stage 2, the digestion time was set at 10 min
for all laboratories.
Scoring of the TMAs was performed according to the
Euro-FISH guidelines with respect to morphology (good,
intermediate, poor/failure), background (absent, acceptable,
excessive/failure), signal intensity (strong, moderate, weak,
absent/failure) and actual score (normal=YY or abnormal=
YYY/YG/YR/GR/YYR/YYG or any other combination
except YYor no score).
Results
Stage 0: probe validation
During stage 0, metaphase slides made from B lymphocytes
of healthy donors were used to validate all 16 probes in
duplicate. Since eight laboratories each tested four probes,
duplicates were independently scored. In order to properly
validate the probes, five metaphases per probe per laboratory
were analysed. All probes localised to the expected position
(Table 1) and no irregularities were found. A selection of the
probes validated in this stage is shown in Fig. 2.
Table 3 Probes assigned to the nine laboratories in such way that
every probe is tested in duplicate
Probe Country code
DE DK/GR ES FR IT NL PT UK
CCND1 ES FR
BCL2 ES IT
BCL3 DK/GR PT
BCL6 IT UK
BCL10 DE FR
MYC DE IT
PAX5 NL UK
MALT1 DE NL
ALK1 DK/GR PT
TCL1 DE NL
IGH FR UK
IGK DK/GR ES
IGL DK/GR PT
TCRAD FR IT
TCRB ES PT
TCRG NL UK
DE Germany, DK Denmark (stage 0), GR Greece (stages 1 and 2), ES
Spain, FR France, IT Italy, NL The Netherlands, PT Portugal, UK
United Kingdom
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Stage 1: robustness of the standardised FISH protocol
To test the robustness of the standardised FISH protocol,
FISH testing was optimised in eight laboratories with every
laboratory using the same four probes as during stage 0.
TMAs used to optimise the protocol were made from
laboratories own samples resulting in centre-specific
TMAs. Stage 1 TMAs were composed of three or four
entities (six cases per entity, if available) per laboratory
supplemented with DLBCL (three cases per TMA) and
reactive tissues (three cases per TMA) resulting in 24 to 30
cores per TMA. In this stage, laboratories used their own
optimal digestion times. Optionally, a 6-min digestion time
(if different from the laboratories own optimal digestion
time) was performed. In total, 1,096 cores were scored in
stage 1. Cores that were lost during the procedure were not
taken into account.
From the results of this stage, it is clear that, in different
laboratories, slightly different digestion times were needed.
In Table 4, results of the laboratory-optimal digestion times
are summarised in combination with the percentage of
reliable scores, resulting in 91% overall reliable scores (805
cores of which 71 could not be scored). Figure 3 shows the
reliability scores of the optimal digestion times per lympho-
ma entity. African BL cases display a very low overall
success percentage of only 60% whereas ALCL, LPL, BL,
FCL and B-CLL/SLL all have a score above 90%.
Although digestion times vary from laboratory to
laboratory, it became clear that, based on the scoring
percentages as summarised in Table 4, a 10-min digestion
time was found to be the optimal digestion time and,
therefore, used in stage 2.
Considering morphology (data not shown), also scored
during stage 1, a higher percentage of nuclei with good mor-
phology was seen using a 10-min digestion time compared
with a 6-min digestion time, 86% and 54%, respectively.
Stage 2: the evaluation of the FISH protocol
throughout Europe
During stage 2, again eight laboratories each used four
probes, providing independent duplicate data per probe.
Every laboratory worked with a 10-min digestion time as
established in stage 1. Four new TMAs were centrally con-
structed, such that every laboratory and every entity was
equally represented on all four TMAs. Each of the four TMAs
included 36 tissue cores. Cores that were lost during the pro-
cedure were not taken into account while analysing the data.
Analysing all 144 cores with all 16 probes in duplicate
showed that one core was repetitively lost resulting in 143
usable cores. Of these 143 cores, the same 14 cores repeatedly
could not be scored reliably in over 50% of the stainings
(9.8%), resulting in an overall 90.2% score reliability. Scoring
percentages per entity are shown in Table 5.
Results per entity
The results for each entity are given in Table 5. Although,
in principle, all samples were fixed and treated in the same
way, some lymphoma entities are more easily lost than
Fig. 2 Selection of probes
validated in stage 0. a BCL10
localises to chromosomal band
1p22; b BCL6 localises to
chromosomal band 3q27;
c ALK localises to chromosomal
band 2p23. a and b A normal
DAPI (DNA) fluorescence
staining combined with the
FISH probe signal. c An
inverted DAPI staining in com-
bination with the FISH probe
signal
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others, as shown by comparing gastric MALT lymphoma to
non-African Burkitt cases (both types starting with 12
cores×16 probes in duplicate=384 cores) with 89 and 0
lost cores, respectively. Furthermore, the MALT cases
appeared to be the most difficult cases to score (82.25%
score reliability) whereas B-CLL/SLL resulted in the
highest percentage (97.38%) of reliably scored cores. Since
the samples, except for the African Burkitt lymphoma
cases, were provided by several laboratories (each by three
laboratories), laboratory-specific effects can be excluded.
African BL, ALCL, LPL, reactive, splenic MZL and T-LBL
all resulted in approximately 88% score reliability. B-CLL/
SLL, DLBCL, FCL, MCL and non-African BL all show a
reliability score of more than 90%.
Table 4 Stage 1 results
Optimal digestion times per
laboratory and per entity.
Number and percentages of
cores with a score and the total
number (No.) of cores scored
after optimal digestion per
laboratory
Entity Country Digestion
time (min)
Cases
with score
Percentage
score
No.
B-CLL Spain 6 44 91.67 48
B-CLL Portugal 10 48 100.00 48
DLBCL Spain 6 23 95.83 24
DLBCL Portugal 10 24 100.00 24
DLBCL Germany 12 11 91.67 12
DLBCL Netherlands 6 9 75.00 12
DLBCL France 6 12 100.00 12
DLBCL Italy 8 12 100.00 12
DLBCL United Kingdom 5 7 77.78 9
FCL Spain 6 44 91.67 48
FCL Italy 8 21 87.50 24
FCL United Kingdom 5 24 96.00 25
MCL Spain 6 38 79.17 48
MCL France 10 5 100.00 5
A-BL Italy 8 12 60.00 20
BL Italy 8 7 87.50 8
BL Germany 12 22 100.00 22
MZL Italy 8 13 65.00 20
MZL France 10 5 100.00 5
MZL United Kingdom 5 28 96.55 29
LPL United Kingdom 5 20 95.24 21
LPL Netherlands 6 22 91.67 24
LPL Germany 12 24 100.00 24
MALT Netherlands 6 17 85.00 20
MALT Germany 12 21 87.50 24
MALT France 10 2 100.00 2
ALCL Portugal 10 47 97.92 48
T-LBL Portugal 10 48 100.00 48
T-LBL Netherlands 6 15 93.75 16
T-LBL Germany 12 19 79.17 24
Reactive Spain 6 24 100.00 24
Reactive Netherlands 6 12 100.00 12
Reactive Portugal 10 18 75.00 24
Reactive Germany 12 12 100.00 12
Reactive Italy 8 9 75.00 12
Reactive France 10 1 100.00 1
Reactive United Kingdom 5 14 100.00 14
Total 734 91.18 805
Fig. 3 Reliability scores of the optimal digestion times per lymphoma
entity
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Disregarding the African BL cases (due to prolonged
fixation), a trend in scorability is noticed with the T cell
lymphomas, the indolent B cell lymphomas and reactive
cases more difficult to score and the aggressive B cell
lymphomas easier to score with FCL taking an intermediate
position.
Discussion
Our study shows that FISH analysis for translocations in
lymphoma is feasible and reliable on formalin-fixed,
paraffin-embedded tissue samples from various laboratories
using a variety of probes using a standardised approach.
The 16 FISH probes that were tested all localised to the
expected position (Table 2). In addition, when every
laboratory used their centre-specific TMA and own optimal
digestion times in combination with the previously chosen
6-min digestion time, over 90% of tests performed could be
scored reliably. This first stage resulted in an overall
preferable 6- or 10-min digestion time and the latter was
chosen for stage 2. To get a higher success rate, the pepsin
digestion time can of course be changed on difficult cases.
As well as during stage 1, during stage 2, when samples
obtained from all laboratories and all lymphoma types
supplemented with reactive cases were equally distributed,
over 90% of all cases could be scored reliably using the
Euro-FISH protocol, rendering this technique very useful
for routine diagnostics. An exception were cases of African
Burkitt lymphoma in which the success rate was lower,
probably due to the prolonged fixation of these cases that
originated from Africa and had been send to Italy for
processing. Of note, the samples were represented on tissue
microarrays that contained cores from different laboratories,
underscoring the robustness of the protocol.
It is of increasing importance to assess the presence of a
chromosomal translocation in the diagnosis and classifica-
tion of lymphomas, especially, since with ongoing im-
provement of patient-tailored therapy one needs to prevent
over- or under-treatment. As we and others have shown,
split-signal FISH is a very fast, reliable and easy-to-use
technique to determine whether a break is present in the
gene of interest. Subsequently, by using other split probes,
fusion probes or split probes for the V genes, it is possible
to determine the translocation partner. A major advantage
of the split-signal probes, as used in our Euro-FISH project,
is that translocations can be made visible which cannot be
detected by other means. For example, in cases of the MLL
gene in leukaemia, cytogenetic information cannot be
detected by polymerase chain reaction (PCR) due to many
(50) possible translocation partners [6]. Furthermore, break-
points spread over a large genomic region, as is the case for
the CCDN1 gene [7], cannot also be easily detected by PCR
analysis. In addition, FISH detection of breakpoints on
paraffin-embedded material is very useful if neither frozen
material nor fresh material is available for classical cytoge-
netic analysis or if no usable results can be obtained by
classical cytogenetics. To illustrate the power of the Euro-
FISH protocol, two case reports are discussed briefly below.
Case 1
A patient, diagnosed with FCL, showed a cytogenetic
aberration of chromosome 14 which was documented as
add(14)(q32). No classical t(14;18) was found by classical
cytogenetics. However, FISH analysis showed that this
Table 5 Stage 2, percentage of reliably scored cores per entity
Entity Digestion
time (min)
Total number
of cores
Number of
cores lost
Number of cores
without a score
Percentage of cores
without score
Percentage of
reliable score
Total
percentage
A-Burkitt 10 288 8 34 12.14 87.86 100.00
ALCL 10 320 8 40 12.82 87.18 100.00
B-CLL 10 384 3 10 2.62 97.38 100.00
DLBCL 10 480 13 26 5.57 94.43 100.00
FCL 10 384 3 36 9.45 90.55 100.00
LPL 10 384 7 46 12.20 87.80 100.00
MALT 10 320 89 41 17.75 82.25 100.00
MCL 10 384 6 18 4.76 95.24 100.00
NA-Burkitt 10 384 0 18 4.69 95.31 100.00
Reactive 10 256 32 29 12.95 87.05 100.00
Splenic MZL 10 384 22 41 11.33 88.67 100.00
T-LBL 10 384 39 39 11.30 88.70 100.00
Total 4,352 230 378 90.83
Lost cores and cores that repeatedly could not be reliably scored in over 50% were not taken into account
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patient had a classical t(14;18)(q32;q21) break with only
the derivative 14 present. This break was later confirmed by
PCR analysis (data not shown).
Case 2
Based on conventional and immunohistochemical stainings,
a second patient was diagnosed with a lymphoma of which
the classification was not sure. FISH analysis on paraffin-
embedded material showed a break for both IgH and BCL2.
Based on these results, the routine staining was repeated
and confirmed the FCL diagnosis already proven by FISH
analysis (data not shown).
In addition to achieving its goal, this study highlighted
some unexpected results. Previously, it was thought that
100% of African BL cases carried the t(8;14)(q21;q32)
translocation [8, 9]. However, we have found that this is not
the case and have identified, in addition to the already
known translocation partner, additional partners for chro-
mosome 8 (Leoncini et al., manuscript submitted, J Pathol).
Further research will establish whether different trans-
locations in BL will need different treatments.
Besides the above-mentioned importance of knowing the
translocation partners, it is also necessary to know whether
other chromosomal aberrations are present. Starostik and
co-workers [10] suggested that t(11;18)-negative MALT
lymphoma, showing numerous allelic imbalances, some of
them identical to aberrations seen in DLBCL, would
eventually transform into high-grade DLBCL. In addition,
deletions of 6q, common in FCL and DLBCL, are
associated with adverse clinical behaviour [11, 12].
An analysis of the effect of a lymphoma pathology panel
revealed that, when all lymphoma diagnoses are centrally
reviewed, 16% of lymphoma patients were incorrectly
diagnosed. In these cases, the revised diagnosis influenced
the treatment of the patient (van Rijk et al., manuscript in
preparation). These incorrect diagnoses could have been
prevented in 50% of the cases by the use of FISH analysis
(own data). We, therefore, propose that FISH analysis be
performed routinely in cases in which the classification is
not completely sure. Our data indicate that translocation
detection is now a mature method that can be implemented
in every department of pathology.
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